Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 2/20 | 0.52 |
| ▸ | GRM6 | O15303 | 2/20 | 0.52 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-Diazo-5-Oxo-L-Norleucine SCHEMBL4281654 | 1.00 | GSR (0.52) | GSRGRM8GRM6GRM7GRM4 | |
| 6-Diazo-5-Oxo-L-Norleucine SCHEMBL9295 | 1.00 | GSR (0.52) | GSRGRM8GRM6GRM7GRM4 | |
| SCHEMBL3052694 | 0.89 | GSR (0.46) | GSRGRM8GRM6GRM7GRM4 | |
| 6-Diazo-5-Oxo-L-Norleucine SCHEMBL8937857 | 0.82 | GRM8 (0.36) | GSRGRM8GRM6GRM7GRM4 | |
| SCHEMBL17918640 | 0.81 | GRM8 (0.52) | GSRGRM8GRM6GRM7GRM4 | |
| Azotomycin SCHEMBL8614187 | 0.81 | NOD1 (0.49) | — | |
| SCHEMBL4078048 | 0.80 | GRIK1 (0.44) | GRIK1GRIA1GRIA2SLC1A3SLC1A2 | |
| SCHEMBL4078056 | 0.80 | GRIK1 (0.44) | GRIK1GRIA1GRIA2SLC1A3SLC1A2 | |
| SCHEMBL28748529 | 0.79 | LTA4H (0.36) | CYP1A2SLC1A1ALDH1A1 | |
| SCHEMBL18476646 | 0.78 | FAAH (0.38) | CYP1A2ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 504 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010771-A | 6-Diazonium-5-oxo-norleucine derivative, preparation method and application | 西北工业大学深圳研究院 | 2026-05-12 | — | — | CN | claimed |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | claimed |
| EP-4560029-A1 | METHOD FOR THE DIAGNOSIS OF ANEURYSM, AND INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF ANEURYSM | Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz (ES) | 2025-05-28 | — | — | EP | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| US-20240424004-A1 | COMBINATION OF TLR LIGANDS, COMPOUNDS LABELLING TUMORS FOR IMMUNE ATTACK, ANTI-CD40 ANTIBODIES AND INHIBITORS OF GLUTAMINE METABOLISM FOR TREATING CANCER | BIOCANIM A S (CZ) | 2024-12-26 | — | — | US | claimed |
| US-20240408114-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY | 2024-12-12 | — | — | US | claimed |
| EP-4433056-A1 | COMBINATION OF TLR LIGANDS, COMPOUNDS LABELLING TUMORS FOR IMMUNE ATTACK, ANTI-CD40 ANTIBODIES AND INHIBITORS OF GLUTAMINE METABOLISM FOR TREATING CANCER | Biocanim A.s. (CZ) | 2024-09-25 | — | — | EP | claimed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| CN-118317773-A | Pharmaceutical composition for treating cancer | 卡尼姆生物有限公司 | 2024-07-09 | — | — | CN | claimed |
| EP-2539456-A1 | INCREASING PLANT GROWTH BY MODULATING OMEGA-AMIDASE EXPRESSION IN PLANTS | Los Alamos National Security, LLC (US) | 2013-01-02 | — | — | EP | claimed |
| US-20120144528-A1 | INCREASING PLANT GROWTH BY MODULATING OMEGA-AMIDASE EXPRESSION IN PLANTS | UNIVERSITY OF MAINE SYSTEM BOARD OF TRUSTEES (US) | 2012-06-07 | — | — | US | claimed |
| WO-2011106794-A1 | INCREASING PLANT GROWTH BY MODULATING OMEGA-AMIDASE EXPRESSION IN PLANTS | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2011-09-01 | — | — | WO | claimed |
| WO-2009124941-A2 | TRYPANOCIDAL COMPOUNDS TARGETED TO TRYPANOSOMES INTERIOR | AARHUS UNIVERSITET (DK) | 2009-10-15 | — | — | WO | claimed |
| US-20070243581-A1 | Process for Producing Dipeptides | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-18 | — | — | US | claimed |
| EP-1760152-A1 | PROCESS FOR PRODUCING DIPEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-03-07 | — | — | EP | claimed |
| US-5695751-A | ADMINISTERING L-AMINO ACID OXIDASE TO REDUCE PLASMA LEVEL OF LARGE AMINO ACIDS TO ALLOW INCREASED TRANSPORT OF LARGE AMINO ACID DRUGS ACROSS BLOOD BRAIN BARRIER | CORNELL RESEARCH FOUNDATION, INC. (US) | 1997-12-09 | — | — | US | claimed |
| EP-0532219-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1996-05-08 | — | — | EP | claimed |
| US-5378455-A | Glutamine metabolism inhibitors using enzymes | CHESEBROUGH-PONDS USA CO., DIVISION OF CONOPCO, INC. (US) | 1995-01-03 | — | — | US | claimed |
| EP-0532219-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1993-03-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | ACACB, SREBF2, FASN | GSR 402/4885GRM8 912/4885GRM6 343/4885 |
| US-20240408114-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | GLS, GLUL, ASNS | GSR 45/4885GRM8 669/4885GRM6 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.